ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidase 4 (DPP4) via the spike (S) protein receptor-binding domain (RBD). The RBD contains critical neutralizing epitopes and serves as an important vaccine target. Since RBD mutations occur in different MERS-CoV isolates and antibody escape mutants, cross-neutralization of divergent MERS-CoV strains by RBD-induced antibodies remains unknown. Here, we constructed four recombinant RBD (rRBD) proteins with single or multiple mutations detected in representative human MERS-CoV strains from the 2012, 2013, 2014, and 2015 outbreaks, respectively, and one rRBD protein with multiple changes derived from camel MERS-CoV strains. Like the RBD of prototype EMC2012 (EMC-RBD), all five RBDs maintained good antigenicity and functionality, the ability to bind RBD-specific neutralizing monoclonal antibodies (MAbs) and the DPP4 receptor, and high immunogenicity, able to elicit S-specific antibodies. They induced potent neutralizing antibodies cross-neutralizing 17 MERS pseudoviruses expressing S proteins of representative human and camel MERS-CoV strains identified during the 2012-2015 outbreaks, 5 MAb escape MERSCoV mutants, and 2 live human MERS-CoV strains. We then constructed two RBDs mutated in multiple key residues in the receptor-binding motif (RBM) of RBD and demonstrated their strong cross-reactivity with anti-EMC-RBD antibodies. These RBD mutants with diminished DPP4 binding also led to virus attenuation, suggesting that immunoevasion after RBD immunization is accompanied by loss of viral fitness. Therefore, this study demonstrates that MERS-CoV RBD is an important vaccine target able to induce highly potent and broad-spectrum neutralizing antibodies against infection by divergent circulating human and camel MERS-CoV strains. 
selection during virus transmission (38) . Consequently, it is possible that key mutations in the RBM of RBD might accumulate in one single virus in the course of viral evolution, resulting in the emergence of immune escape virus strains. Thus, to improve our understanding of virus escape mutants relative to viral fitness, it is important to establish whether simultaneous changes of multiple key residues in the RBM of RBD will alter the antigenicity, functionality, and immunogenicity of the RBD.
In this study, we initially constructed five recombinant RBD proteins, designated 2012-RBD, 2013-RBD, 2014-RBD, 2015-RBD, and Camel-RBD. They contain single or multiple mutations in the RBD of representative human MERS-CoV strains circulating in the 2012, 2013, 2014, and 2015 outbreaks or several mutations noted in the camel RBD. We evaluated whether RBDs with these scattered mutations would maintain their antigenicity, functionality, and immunogenicity. We also evaluated the crossneutralizing activity of the antibodies induced by these RBDs against divergent human and camel MERS-CoV strains, as well as antibody escape mutants of MERSCoV. Two additional RBDs, RBD-FGG and RBD-FGGAA, which contain mutations of 3 and 5 key residues in the RBM of RBD, respectively, were constructed. Our results demonstrate strong cross-reactivity when mice were immunized with wild-type or variant RBDs. They demonstrate that RBD mutations with diminished DPP4 binding also led to virus attenuation, suggesting that immunoevasion after RBD immunization may result only in the context of loss of viral fitness.
RESULTS
Recombinant RBD proteins of representative human and camel MERS-CoV strains in 2012 to 2015 maintained good conformation and antigenicity. The RBD sequences of MERS-CoVs isolated from various infection regions, different time periods (2012 to 2015), and different hosts (humans and camels) are slightly different from the RBD sequence of EMC2012, the prototype strain. The mutations are summarized in Table 1 .
Accordingly, we initially constructed 5 recombinant RBD (rRBD) proteins (2012-RBD, 2013-RBD, 2014-RBD, 2015-RBD, and Camel-RBD) containing single and multiple natural mutations in the critical neutralizing domain (CND) of RBD of representative human MERS-CoV strains isolated from 2012 to 2015 and representative camel MERS-CoV strains, respectively (Table 2 ; Fig. 1A and B). These proteins, which were fused with a C-terminal human Fc tag, were characterized by SDS-PAGE and Western blot analysis. Similar to the wild-type RBD (EMC-RBD), the five RBD mutants of native (nonboiled) proteins had twice the molecular mass of those that were boiled (denatured) proteins (Fig. 1C, top) , suggesting that the Fc tags promoted dimer formation. In addition, all RBD proteins of human and camel MERS-CoVs reacted strongly with antibodies targeting the RBD of MERS-CoV EMC2012 (Fig. 1C, bottom) .
To investigate whether the above-mentioned rRBD proteins of divergent human and camel MERS-CoV strains maintained good antigenicity, we performed an enzymelinked immunosorbent assay (ELISA) to test the binding activity of these proteins to EMC2012 RBD-specific neutralizing MAbs (33, 34) . All mutant and wild-type RBDs bound strongly to mouse MAb Mersmab1 and human MAbs m336, m337, and m338 (Fig. 1D) , demonstrating good antigenicity.
Variant rRBD proteins bound strongly to human DPP4 receptor. A coimmunoprecipitation (Co-IP) assay was initially performed to identify whether the rRBD proteins of representative human and camel MERS-CoV strains circulating in 2012 to 2015 could bind to DPP4, the receptor of MERS-CoV. Strong reactivity to both proteins was observed in the immunoprecipitated samples containing RBD and hDPP4 or RBD and hDPP4-expressing Huh-7 cell lysates. However, hDPP4 in the absence of RBD was recognized only by anti-hDPP4 antibody, not by anti-MERS-CoV-RBD antibody ( Fig. 2A) . These data suggest that rRBD proteins of representative human and camel MERS-CoV strains in 2012 to 2015 bound efficiently to soluble and cell-associated hDPP4 receptors.
ELISA and flow cytometry assays were then carried out to quantify the binding between RBD and DPP4. ELISA results demonstrated that the RBDs from multiple human and camel MERS-CoVs bound to both hDPP4 (Fig. 2B ) and camel DPP4 (cDPP4) (Fig. 2C) proteins in a dose-dependent manner and that the binding to hDPP4 was much stronger than that of cDPP4 protein. In contrast, no binding was observed between human Fc and hDPP4 or cDPP4 ( Fig. 2B and C) . Results from flow cytometry analysis also revealed strong binding of these rRBD proteins to Huh-7 cell-associated hDPP4 receptor (Fig. 2D) . Taken together, these results confirm the binding specificity and potency between human or camel MERS-CoV RBDs and the hDPP4 receptor.
Recombinant RBD proteins of representative MERS-CoV strains in 2012 to 2015 induced highly potent cross-reactive antibody responses. The purified rRBD proteins were then evaluated for their capacity to induce cross-reactive antibody responses in immunized mouse sera. All RBDs elicited similarly high titers of IgG antibodies that cross-reacted potently with S1 protein of MERS-CoV EMC2012 (Fig. 3A) . Similar to EMC-RBD, 2012-RBD, 2014-RBD, 2015-RBD, and Camel-RBD all induced potent S1-specific IgG1 (Th2) and IgG2a (Th1) antibody responses. In addition, 2013-RBD, which contained 5 mutations spread throughout the RBD, still elicited strong IgG1 and IgG2a antibodies specific to S1 of the EMC2012 strain ( Fig. 3B and C) . In contrast, phosphatebuffered saline (PBS) control induced only background levels of MERS-CoV-specific antibody ( (Table 1 ). We then tested the ability of the aforementioned RBD-immunized mouse sera to prevent infection of these pseudoviruses in Huh-7 cells. All pseudoviruses efficiently expressed MERS-CoV RBD and HIV-1 p24, which are recognized by anti-RBD antibody (Fig. 4A , top) and p24-specific antibody (Fig. 4A , bottom), and had sufficient infectivity in hDPP4-expressing Huh-7 cells (Fig. 4B ). As expected, EMC-RBD, the RBD of EMC2012, the prototypic MERS-CoV, induced highly potent neutralizing antibodies that crossneutralized all 17 pseudoviruses of MERS-CoV strains tested, including those isolated from humans in Saudi Arabia and South Korea in the 2012-2015 outbreaks and those from infected camels ( bodies than did the other RBDs, these antibodies could still efficiently cross-neutralize all MERS pseudoviruses tested (Fig. 5C ). In contrast, no specific neutralizing antibody was induced in PBS-treated (control) mice (Fig. 5A) . These results confirm the ability of the test rRBD proteins in inducing strong and cross-neutralizing antibodies against divergent MERS-CoV strains isolated from humans and camels.
Recombinant RBD proteins of 2012-2015 MERS-CoV strains induced highly potent cross-neutralizing antibodies against MERS-CoV MAb escape variants.
Polyclonal anti-MERS-CoV antibody is expected to neutralize MAb escape variants, since many sites on the RBD are targeted in such a preparation. To assess this, we generated 5 pseudoviruses expressing S proteins of MAb escape mutants with single or multiple (Fig. 7) . These data show that infectious viruses, as well as pseudoviruses, were neutralized after immunization with a panel of RBDs.
WT), both mutant proteins had high purity, formed conformational dimeric structures (Fig. 8A, top) , and were recognized by RBD-specific antibodies (Fig. 8A, bottom) . Then, we tested their binding activity to DPP4 by ELISA and flow cytometry analyses. The results revealed that RBD-FGG and RBD-FGGAA exhibited significantly reduced binding activity to recombinant hDPP4 (Fig. 8B), cDPP4 (Fig. 8C) , and cell-associated hDPP4 (Fig.  8D ) proteins, with effects most obvious when 5 residues were mutated ( Fig. 8B to D) .
To evaluate the effects of these mutations on S-mediated viral entry, we constructed 2 additional MERS pseudoviruses expressing S proteins with the 3 or 5 aforementioned mutations in RBD and used them to infect Huh-7 cells. These MERS-CoV mutant pseudoviruses were significantly inhibited from entering Huh-7 cells, with the greatest inhibition observed after infection with pseudovirus carrying 5 mutations (Fig. 8E) .
The MERS-CoV RBD with mutations of multiple key residues in the RBM exhibited significantly reduced antigenicity and neutralizing immunogenicity. To determine whether simultaneous mutations of key residues in the RBM affected antigenicity, we initially evaluated the binding affinity of mutant RBD proteins (RBD-FGG and RBD-FGGAA) to wild-type RBD-specific neutralizing monoclonal and polyclonal antibodies by ELISA. Compared to EMC-RBD WT, the two mutant RBDs exhibited significantly reduced binding to neutralizing MAbs Mersmab1 and m336 (Fig. 9A) . Both mutant RBDs bound less well than wild-type RBD to polyclonal sera, with the greatest reduction observed when RBD-FGGAA was assayed (Fig. 9B) .
Then, we further investigated whether RBD-FGG and RBD-FGGAA were as immunogenic as wild-type RBD. First, we examined whether MAbs Mersmab1 and m336 efficiently neutralized pseudoviruses with RBD-FGG and RBD-FGGAA mutations. The results demonstrated (by comparing 50% neutralizing doses [ND 50 ]) that the pseudoviruses with these mutations were significantly less sensitive to neutralization than wild-type pseudoviruses (Fig. 9C) . Similar results were obtained when the pseudoviruses were exposed to mouse sera containing polyclonal neutralizing antibodies (Fig.  9D) . After immunization, RBD-FGG and RBD-FGGAA elicited significantly decreased levels of IgG (Fig. 9E ) and neutralizing antibodies in mouse sera against MERS pseudovirus (EMC2012 WT) (Fig. 9F) . These results suggest that simultaneous mutations of multiple key residues in the RBM of MERS-CoV RBD resulted in significantly reduced antigenicity and neutralizing immunogenicity, but at the cost of reduced ability to enter cells.
DISCUSSION
Development of safe, effective, and broad-spectrum vaccines against MERS-CoV infection is still urgently needed to combat the continuing threat posed by MERS-CoV. Compared with other vaccine types, including those based on viruses and viral vectors, subunit vaccines are safer since viral genomic components are absent (25, 28) . We previously identified the RBD in the S protein of MERS-CoV as a critical vaccine target and demonstrated that RBD-based MERS vaccines induce highly potent neutralizing antibodies that protect immunized animals against MERS-CoV challenge (20, 21, 23, 24, 40) .
Studies have revealed the presence of a number of single and multiple mutations in the RBDs of MERS-CoV strains isolated from humans and camels at different time periods during the 2012-2015 outbreaks (Table 1) (29, 30) . Also, analysis of RBD-specific neutralizing MAbs has identified a number of mutations in the RBDs of MERS-CoV mutants that escaped neutralization by these MAbs (31-34) . The presence of both natural and antibody escape mutations in the RBD of MERS-CoV has raised concerns (Tables 1 and 2 ). Our data indicated that all five mutant RBDs maintained good conformation and antigenicity, reacting strongly with polyclonal and MAb neutralizing antibodies that recognize neutralizing epitopes in the RBD of strain EMC2012 (33, 34, The infectivity of EMC2012 WT pseudovirus in Huh-7 cells was set as 100% entry, and the infectivity of the corresponding mutant pseudovirus was expressed as the percentage of entry (%). ***, P Ͻ 0.001 between mutant and WT pseudoviruses. 41 ). In addition, these RBDs bound strongly to the hDPP4 receptor in soluble and cell-associated forms, suggesting good functionality. It should be noted that while the binding between these RBDs and hDPP4 protein was stronger than that between RBDs and cDPP4 protein, the binding between Camel-RBD and hDPP4-expressing Huh-7 cells was enhanced, not reduced. These results suggest that the camel RBD retains its high binding activity to human receptor during evolution, indicating that camels will remain an important reservoir for sporadic human infection.
MERS vaccines are expected to have broad-spectrum neutralizing ability against different MERS-CoV strains. Indeed, we have found that similar to the prototype FIG 9 MERS-CoV RBD with multiple mutations of key residues in the RBM showed reduced antigenicity and neutralizing immunogenicity. (A and B) Detection of the binding between mutant RBD proteins and RBD-specific neutralizing antibodies by ELISA. ELISA plates were precoated with rRBD proteins (1 g/ml), and binding was detected using RBD-specific neutralizing MAbs Mersmab1 and m336 (1.25 g/ml) (A), as well as polyclonal antibodies from sera of mice immunized with EMC-RBD wild-type (WT) protein (B). Serum IgG antibody titers are expressed as the endpoint dilutions that remain positively detectable, and the data are presented as means Ϯ SD (n ϭ 4) of each RBD binding to the antibodies. EMC-RBD WT protein was included as a control. **, P Ͻ 0.01; ***, P Ͻ 0.001 between mutant and WT RBD proteins. (C and D) Detection of neutralizing activity of MERS-CoV RBD-specific neutralizing MAbs Mersmab1 and m336 (C), as well as polyclonal antibodies from sera of mice immunized with EMC-RBD WT protein (D), against the above-described mutant and WT pseudoviruses. ND 50 and NT 50 represent the 50% neutralizing dose (for MAbs) and 50% neutralizing antibody titers (for sera), respectively. **, P Ͻ 0.01; ***, P Ͻ 0.001 between mutant and WT pseudoviruses. (E and F) Detection of IgG (E) and neutralizing antibodies (F) induced by MERS-CoV RBD mutant proteins, or EMC-RBD WT protein control, by ELISA and MERS pseudovirus neutralization assay, respectively. Sera from 10 days after the second immunization were tested for IgG antibodies specific to EMC-RBD and neutralizing antibodies against EMC2012 WT pseudovirus. The antibody titers are presented as means Ϯ SD for five mice in each group. The neutralizing antibody titers are expressed as mean NT 50 Ϯ SD for five mice in each group. *, P Ͻ 0.05; **, P Ͻ 0.01 between mutant and WT RBD proteins.
EMC-RBD, all five mutant RBDs containing scattered key mutations elicited high-titer antibody responses in immunized mice as assessed by their ability to strongly crossreact with MERS-CoV S protein from the prototype strain EMC2012. -2012) . Therefore, irrespective of these scattered mutations at single or multiple sites of MERS-CoV RBD, the data presented here suggest that RBD-based MERS vaccines will be able to induce sufficient cross-neutralizing antibodies for protection against current circulating strains, as well as other strains that might occur in the future.
The tertiary structure of MERS-CoV S trimer was modeled on the basis of the recently solved cryo-electron microscopy (cryo-EM) structure of mouse hepatitis virus (MHV) S trimer ( Fig. 10) (42) . Mapping of these naturally occurring scattered mutations in RBD of MERS-CoV on the modeled structure of MERS-CoV S trimer revealed that eight of these residues (506, 509, 510, 520, 522, 529, 530, and 534) are located in the RBM region whereas the rest are located in the core region of the RBD. Among these eight RBM residues, three (506, 509, 510) are directly involved in DPP4 binding (35, 36) . The epitopes covering these three residues have been shown to be critical for the binding of neutralizing monoclonal antibodies (32) (33) (34) . Two additional key residues (511 and 513) in the RBM are also responsible for virus-DPP4 binding and play a role in inducing MAb escape mutant virus strains (31, 32, 34) . Thus, simultaneous mutations of the above-mentioned three (506, 509, 510) or five (506, 509, 510, 511, 513) key residues in a single viral strain led to significant changes in the neutralizing immunogenicity of MERS-CoV RBD, facilitating escape of the virus from host immune surveillance. Several reasons explain why this has not happened in nature. First, the chance for simultaneous mutations of these three or five key residues in the RBM of the RBD is significantly lower than that for single mutations. Second, we found that mutating all three or five residues simultaneously significantly reduced viral binding to the DPP4 receptor and, hence, 4L3N ) and the corresponding domain in the trimeric MHV S (PDB access code 3JCL), the crystal structure of the former was modeled into the cryo-EM structure of the latter. The core structure of MERS-CoV RBD is in cyan, the RBM is in red, and the MERS-CoV RBD residues that have undergone mutations are in blue. The trimeric MHV S protein contains three copies of this domain, with two colored in magenta and the third replaced by MERS-CoV RBD.
reduced the ability of the virus to enter and infect target cells, a hefty price that the virus cannot afford to pay. Consequently, only scattered mutations of these residues were detected in different viral strains, which led to less significant changes in the neutralizing immunogenicity of each RBD. The other mutated residues play less important roles in receptor binding and in overall neutralizing immunogenicity of the RBD and are also inconsistently detected in different viral strains. Since these binding and inhibition assays were based on viral RBD protein or pseudoviruses expressing MERSCoV S protein with the test mutations in the RBD, there exists the possibility that the results might be different when mutations are identified in live MERS-CoV. It is also possible that some live MERS-CoV strains that contain the mutations of key residues in RBD might become resistant to neutralizing antibodies without causing significant reduction of infectivity. Nevertheless, the results presented in this study suggest that it might take much longer for MERS-CoV to acquire immune escape mutations in the RBD than in other regions of the viral S protein since decreased neutralization is accompanied by reduced binding to DPP4. Therefore, the RBD remains a major target site for development of MERS vaccines.
MERS-CoV RBD contains multiple conformational neutralizing epitopes encompassing key residues that include L506, D509, D510, R511, E513, W535, E536, D539, Y540, and R542 (33, 34, 41, (43) (44) (45) ; thus, vaccines targeting the RBD are effective against a virus with mutations in one or more epitopes. In contrast, other target sites in the S protein may contain only one single neutralizing epitope. Therefore, vaccines targeting such an epitope would become ineffective if a single mutation occurred. In addition, the RBD is also a critical functional domain, and antibodies targeting the RBD can also block the binding between RBD and viral receptor, in addition to their virus-neutralizing activity (26) .
To summarize, we constructed five rRBD proteins respectively covering different mutations in the RBD of MERS-CoV that circulated during the course of the 2012-2015 outbreaks, as well as two mutant RBDs with simultaneous mutations of multiple key residues in the RBM of the RBD. Their antigenicity to bind MERS-CoV RBD-specific neutralizing antibodies, as well as their functionality to bind the DPP4 receptor of MERS-CoV, was demonstrated. This study also explored the broad-spectrum capability of the RBDs containing naturally scattered mutations in inducing cross-neutralizing antibodies against human and camel strains isolated from the 2012-2015 outbreaks, as well as antibody escape mutant strains. Taken together, this study confirms the feasibility of developing an RBD-based MERS vaccine that is safe, effective, and broadspectrum, with the added ability to cross-neutralize antibodies against infection of current and future divergent MERS-CoV strains.
MATERIALS AND METHODS
Ethics statement. Female BALB/c mice aged 6 to 8 weeks were used in this study. The animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH), and the protocol was approved by the Committee on the Ethics of Animal Experiments of the New York Blood Center (permit number 194.17).
Sources of sequences. The MERS-CoV S sequences from years 2012 through 2015 were obtained from the GenBank database at the NCBI website (https://www.ncbi.nlm.nih.gov) and aligned with the S protein sequence of MERS-CoV EMC2012 strain to identify key mutations within residues 377 to 588 of the RBD (Table 1) .
Construction, expression, and purification of recombinant proteins. Construction, expression, and purification of recombinant proteins was performed as previously described with some modifications (21, 40) . Briefly, the MERS-CoV EMC-RBD plasmid was constructed by fusing residues 377 to 588 of EMC2012 RBD with human IgG Fc. This plasmid was used as the template to generate 2012-RBD, 2013-RBD, 2014-RBD, 2015-RBD, and Camel-RBD with point or multiple natural mutations, as well as to generate RBD-FGG and RBD-FGGAA with simultaneous multiple mutations of key RBM residues (Table 2) , using a QuikChange site-or multisite-directed mutagenesis kit (Agilent Technologies). Recombinant S1 of MERS-CoV (EMC2012) (residues 18 to 725) and cDPP4 with a C-terminal His 6 were constructed using the pJW4303 expression vector (26) . The aforementioned proteins were harvested from 293T cell culture supernatants. Recombinant hDPP4 protein (residues 39 to 766) containing a C-terminal His 6 was expressed in the culture medium of insect cells using the Bac-to-Bac expression system (Invitrogen) (19) . The Fc-and His-tagged proteins were purified by protein A affinity chromatography (GE Healthcare) and nickel-nitrilotriacetic acid (Ni-NTA) Superflow (Qiagen), respectively.
